Somewhat Positive News Coverage Somewhat Unlikely to Impact AbbVie (ABBV) Share Price
Media stories about AbbVie (NYSE:ABBV) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AbbVie earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.1103676250931 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Most Recent Analysts Ratings AbbVie Inc. (ABBV) (nismagazine.com)
- Lagoon boon swoon: Data from Murano helps Abbvie, waters in CLL still churning (bioworld.com)
- Stocks that deserve a closer look under the hood: AbbVie Inc. (ABBV), JetBlue Airways Corporation (JBLU) – Market Movers (financialqz.com)
- AbbVie Inc.: AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with … – The Wall Street Transcript (twst.com)
- AbbVie Makes Progress on Quest to Diversify (fool.com)
Several analysts have issued reports on ABBV shares. Evercore ISI started coverage on shares of AbbVie in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $95.00 price target on the stock. BidaskClub upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 6th. Jefferies Group restated a “buy” rating and issued a $94.00 price target on shares of AbbVie in a research report on Friday, September 8th. Goldman Sachs Group restated a “buy” rating and issued a $100.00 price target (up from $85.00) on shares of AbbVie in a research report on Friday, September 8th. Finally, Cowen reiterated a “hold” rating and set a $95.00 target price (up from $70.00) on shares of AbbVie in a research report on Monday, September 11th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. AbbVie presently has an average rating of “Buy” and an average target price of $97.96.
Shares of AbbVie (ABBV) traded up $1.05 during trading on Wednesday, hitting $97.35. 6,116,012 shares of the stock traded hands, compared to its average volume of 6,094,413. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45. AbbVie has a 1-year low of $59.27 and a 1-year high of $98.52. The firm has a market cap of $154,007.59, a price-to-earnings ratio of 18.17, a P/E/G ratio of 1.34 and a beta of 1.52.
AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The business had revenue of $7 billion for the quarter, compared to analyst estimates of $7 billion. During the same period in the previous year, the business earned $1.21 EPS. The firm’s revenue was up 8.8% on a year-over-year basis. sell-side analysts predict that AbbVie will post 5.55 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be issued a dividend of $0.71 per share. This is an increase from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 annualized dividend and a yield of 2.92%. The ex-dividend date is Thursday, January 11th. AbbVie’s dividend payout ratio (DPR) is currently 62.29%.
In related news, VP Robert A. Michael sold 6,699 shares of AbbVie stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $88.00, for a total transaction of $589,512.00. Following the completion of the transaction, the vice president now directly owns 10,007 shares of the company’s stock, valued at approximately $880,616. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Henry O. Gosebruch sold 18,300 shares of AbbVie stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the transaction, the insider now directly owns 81,287 shares of the company’s stock, valued at $7,360,537.85. The disclosure for this sale can be found here. Insiders have sold a total of 268,825 shares of company stock valued at $25,186,090 over the last three months. 0.23% of the stock is currently owned by insiders.
WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-abbvie-abbv-share-price/1762096.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with Analyst Ratings Network's FREE daily email newsletter.